• Poster 1 presents Early Access Program (EAP) data for 111 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
• Poster 2 details the Phase 2b randomized, double-blinded study evaluating MaaT033 to enhance overall survival in allogenic hematopoietic cell transplantation patients.
• For the seventh consecutive year, MaaT Pharma's abstracts have been selected for presentation at the ASH Annual Meeting, reinforcing the Company's leadership in microbiome/hematology-oncology.

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to enhancing survival for patients with cancer, announced today that extended results from its Early Access Program of MaaT013 in 111 patients (additional 30 patients included in the Program compared to last year) with aGvHD and the design of its Phase 2b study evaluating MaaT033 in improving overall survival in patients undergoing allogenic hematopoietic cell transplantation (allo-HSCT) have been selected for poster presentations at the 65^th American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. This is the seventh year in a row that the Company’s clinical data and activities have been selected for a presentation at the ASH Annual Meeting, the world-leading event in malignant and non-malignant hematology, demonstrating the ongoing interest from clinicians for microbiome modulation approaches in the hemato-oncology field.

In line with the conference embargo policy, MaaT Pharma will detail the presented results through a press release on Monday, December 11^th, 2023. The Company will also host an investor webcast on Monday, December 18^th, 2023, at 6:00pm CET (further details to follow).

The EAP results include data from 111 patients with steroid-resistant or steroid-dependent aGvHD treated with MaaT013, previously unresponsive to 1-6 lines of therapy. MaaT013 is currently being evaluated in a pivotal Phase 3 trial (n=75) for corticosteroid- and ruxolitinib-refractory gastrointestinal aGvHD. The Company shared the positive review by DSMB in October 2023 for this Phase 3 trial, including a favorable benefit/risk ratio, with a good safety profile and positive preliminary efficacy results. As of today, over 170 patients have been safely treated with MaaT013 in Europe in clinical trials and the EAP.

The Company provides an update on MaaT033, an oral ecosystem microbiome capsule for adjunctive therapy, and will share the design of the Phase 2b trial, the largest randomized clinical trial (RCT) study for a microbiome therapy in hemato-oncology to date with the enrollment of 387 patients, investigating the efficacy of MaaT033 in improving overall survival for patients receiving allo-HSCT.

Poster Presentations:

MaaT013

• Title: Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe
• Poster number: 3553
• Presenter: Professor Florent Malard, hematology professor at the Saint-Antoine Hospital and Sorbonne University
• Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
• Session Date/Time: Sunday, December 10, 2023: 6:00pm -8:00pm EST
• Location: San Diego Convention Center, Halls G-H

MaaT033

• Title: A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating the Efficacy and Safety of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy in Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: The Phoebus Trial
• Poster number: 4947
• Presenter: Professor Florent Malard, hematology professor at the Saint-Antoine Hospital and Sorbonne University
• Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
• Session Date/Time: Monday, December 11, 2023: 6:00pm -8:00pm EST
• Location: San Diego Convention Center, Halls G-H

Upcoming scientific conference participations

• November 1-5, 2023 – 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting - Posters presentations
• November 15-17, 2023 – 22^nd Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) Congress - Booth #12
• December 9-12, 2023 - 65^th American Society of Hematology (ASH) Annual Meeting- Posters presentations

About MaaT Pharma

MaaT Pharma, a leading clinical-stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma initiated an open-label, single-arm Phase 3 clinical trial in patients with acute GvHD, building on the positive results of its Phase 2 proof-of-concept. Its powerful discovery and analysis platform, gutPrint^®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102989593/en/